Eyeworld

WE'LL KEEP THE DOSE ON DELIVERING SUSTAINED STEROID COVERAGE, FOR A HANDS-FREE POST-OP EXPERIENCE. 1,2 DEXTENZA is designed to: • Allow for physician-controlled administration 1 • Provide preservative-free, sustained coverage for up to 30 days 2 INDICATION DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis. WARNINGS AND PRECAUTIONS Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment. Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. ADVERSE REACTIONS The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%). The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%). Please see brief summary of full Prescribing Information on adjacent page. References: 1. Sawhney AS, Jarrett P, Bassett M, Blizzard C, inventors; Incept, LLC, assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013. 2. DEXTENZA [package insert). Bedford. MA: Ocular Therapeutlx, Inc: 2019. © 2020 Ocular Therapeutix, Inc. All rights reserved. DEXTENZA is a registered trademark of Ocular Therapeutix, Inc. PP-US-DX-0230-V2

• Blank Page
• Blank Page (1)